Supreme Court Questions Massive Medicine Markups, Floats 16% MRP Cap Above Retailer Price

The Supreme Court questioned the Centre over steep markups on cancer drugs and other medicines and asked why Maximum Retail Price should not be capped at 16 percent above the price to retailer.

What happened

The Supreme Court questioned the Centre over steep markups on cancer drugs and other medicines and asked why Maximum Retail Price should not be capped at 16 percent above the price to retailer. The Bench focused on the gap between procurement or retailer prices and amounts ultimately charged, particularly where government health schemes reimburse treatment. The Court's remarks are part of ongoing proceedings and do not yet create a binding nationwide price cap. The Centre must respond to the pricing concern and existing regulatory framework. The case may significantly affect medicine-price regulation, hospital billing practices and public expenditure on high-cost treatment.

Legal significance

The legal effect is confined to the present judgment, order or procedural development. Party allegations and submissions are not treated as established facts.

Practical consequence

The matter proceeds according to the operative direction, statutory process or next hearing described above.

Source: Original report